Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL20305480 | 0.99 | ALDH1A1 (0.47) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| SCHEMBL3490799 | 0.93 | ALDH1A1 (0.46) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| SCHEMBL10340280 | 0.92 | HDAC1 (0.47) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| SCHEMBL21768790 | 0.88 | ALDH1A1 (0.51) | ALDH1A1PKMMAPTKMT2AHSD17B10 | |
| SCHEMBL44725 | 0.88 | ALDH1A1 (0.50) | ALDH1A1PKMHDAC1HDAC2MAPT | |
| SCHEMBL28630260 | 0.87 | HDAC1 (0.41) | ALDH1A1PKMHDAC1HDAC2TP53 | |
| SCHEMBL327593 | 0.84 | HPGD (0.44) | ALDH1A1PKMHDAC1HDAC2HPGD | |
| SCHEMBL2002797 | 0.83 | ALDH1A1 (0.49) | ALDH1A1PKMMAPTKMT2AHSD17B10 | |
| SCHEMBL16047480 | 0.81 | HDAC1 (0.34) | ALDH1A1HDAC1HDAC2MAPTKMT2A | |
| SCHEMBL616908 | 0.81 | ALDH1A1 (0.54) | ALDH1A1PKMMAPTKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704904-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260034253-A1 | NECTIN-4 MINIPROTEIN CONJUGATES | AKTIS ONCOLOGY INC (US) | 2026-02-05 | — | — | US | claimed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | claimed |
| EP-4580684-A1 | DRUG CONJUGATES OF HUMANIZED ANTI PVR ANTIBODIES | Nectin Therapeutics Ltd. (IL) | 2025-07-09 | — | — | EP | claimed |
| EP-4551255-A2 | NECTIN-4 MINIPROTEIN CONJUGATES | Aktis Oncology, Inc. (US) | 2025-05-14 | — | — | EP | claimed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | claimed |
| US-20250009890-A1 | TRANS-CYCLOOCTENE-MODIFIED BISPECIFIC ANTIBODIES | TAMBO, INC. | 2025-01-09 | — | — | US | claimed |
| WO-2024249501-A2 | B7H3 MINIPROTEIN CONJUGATES | AKTIS ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024229427-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024168065-A1 | SYSTEM COMPRISING MODIFIED WHOLE CELL PAYLOADS FOR TARGETED DELIVERY | TAMBO, INC. (US) | 2024-08-15 | — | — | WO | claimed |
| EP-2437790-B1 | CONJUGATION METHODS | IMMUNOGEN INC (US) | 2019-02-20 | — | — | EP | claimed |
| EP-2675480-B1 | METHODS OF PREPARATION OF CONJUGATES | IMMUNOGEN INC (US) | 2018-12-26 | — | — | EP | claimed |
| EP-2968590-B1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2018-09-05 | — | — | EP | claimed |
| US-9387261-B2 | Immunoconjugates targeting CD138 and uses thereof | BIOTEST AG (DE) | 2016-07-12 | — | — | US | claimed |
| US-9353127-B2 | Methods of preparation of conjugates | IMMUNOGEN, INC. (US) | 2016-05-31 | — | — | US | claimed |
| US-20160046721-A1 | ANTIBODIES AND METHODS FOR TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2016-02-18 | — | — | US | claimed |
| EP-2976362-A1 | ANTIBODIES AND METHODS FOR TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | Beijing Shenogen Pharma Group Ltd. (CN) | 2016-01-27 | — | — | EP | claimed |
| EP-2399609-B1 | Process for preparing maytansinoid antibody conjugates | IMMUNOGEN INC (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2014146575-A1 | ANTIBODIES AND METHODS FOR TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2014-09-25 | — | — | WO | claimed |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC. (US) | 2011-06-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034253-A1 | NECTIN-4 MINIPROTEIN CONJUGATES | NECTIN4, FUT4, SDC4 | ALDH1A1 4445/4885PKM 3700/4885HDAC1 3851/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | ALDH1A1 1023/4885PKM 843/4885HDAC1 1946/4885 |
| US-20250009890-A1 | TRANS-CYCLOOCTENE-MODIFIED BISPECIFIC ANTIBODIES | FCGR3B, PDCD10, PDCD1 | ALDH1A1 4421/4885PKM 4232/4885HDAC1 3487/4885 |
| US-20160046721-A1 | ANTIBODIES AND METHODS FOR TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | GPER1, ESRRG, ESR1 | ALDH1A1 1783/4885PKM 4400/4885HDAC1 2626/4885 |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | SPR, HCCS, TXNRD1 | ALDH1A1 707/4885PKM 4503/4885HDAC1 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.